
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
New day dawns for residents. Welfare reform: Plus and minus. Key asthma guidelines, now revised. Eye on Washington






